Is Ambalal Sarabhai Enterprises a good stock to invest in?

Ambalal Sarabhai Enterprises can be analyzed on the following key metrics - TTM P/E: 33.75 Sector P/E: 31.15 Dividend Yield: 0% D/E ratio: -

Ambalal Sarabhai Enterprises Share Price

Sector: Major Drugs

Powered by

55.48 -0.37 (-0.66%)

1D
5D
1M
3M
6M
1Y
5Y
MAX

Price Range

Today’s Low 53

Today’s High 56.65

52 Week Low 37.54

52 Week High 77.7

Key Metrics

Market Cap (In Cr) 428
Beta 0.48
Div. Yield (%) 0
P/B 3.12
TTM P/E 33.75
Peg Ratio -0.82
Sector P/E 31.15
D/E 0.37
Open Price 56.6
Prev Close 55.85

View All Metrics

Ambalal Sarabhai Enterprises Analysis

Price Analysis

1 Week

-6.53%
3 Months

-9.16%
6 Month

17.46%
YTD

46.9%
1 Year

19.9%

Risk Meter

62% Low risk
62% Moderate risk
62% Balanced Risk
62% High risk
62% Extreme risk

Ambalal Sarabhai Enterprises Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2024

Total Revenue
173.57

Selling/ General/ Admin Expenses Total
27.7

Depreciation/ Amortization
3.57

Other Operating Expenses Total
38.54

Total Operating Expense
170.83

Operating Income
2.74

Net Income Before Taxes
6.65

Net Income
5.68

Diluted Normalized EPS
0.74

Period
2023

Total Revenue
170.28

Selling/ General/ Admin Expenses Total
56.02

Depreciation/ Amortization
2.76

Other Operating Expenses Total
-1.2

Total Operating Expense
161.49

Operating Income
8.79

Net Income Before Taxes
14.83

Net Income
11.1

Diluted Normalized EPS
1.44

Period
2022

Total Revenue
196.75

Selling/ General/ Admin Expenses Total
54.33

Depreciation/ Amortization
2.32

Other Operating Expenses Total
-1.13

Total Operating Expense
186.34

Operating Income
10.41

Net Income Before Taxes
54.19

Net Income
47.22

Diluted Normalized EPS
4.53

Period
2021

Total Revenue
163.64

Selling/ General/ Admin Expenses Total
62.8

Depreciation/ Amortization
2.41

Other Operating Expenses Total
-0.87

Total Operating Expense
165.09

Operating Income
-1.45

Net Income Before Taxes
32.54

Net Income
29.36

Diluted Normalized EPS
1.53

Period
2020

Total Revenue
133.5

Selling/ General/ Admin Expenses Total
54.1

Depreciation/ Amortization
2.57

Other Operating Expenses Total
0.3

Total Operating Expense
136.86

Operating Income
-3.36

Net Income Before Taxes
14.94

Net Income
14.06

Diluted Normalized EPS
1.8

Period
2019

Total Revenue
151.88

Selling/ General/ Admin Expenses Total
53.28

Depreciation/ Amortization
2.1

Other Operating Expenses Total
1.7

Total Operating Expense
147.11

Operating Income
4.77

Net Income Before Taxes
8.21

Net Income
4.25

Diluted Normalized EPS
0.55

Period
2018

Total Revenue
125.62

Selling/ General/ Admin Expenses Total
28.05

Depreciation/ Amortization
2.12

Other Operating Expenses Total
39.15

Total Operating Expense
139.52

Operating Income
-13.9

Net Income Before Taxes
7.96

Net Income
1.28

Diluted Normalized EPS
-1.06

View detailed financials

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Ambalal Sarabhai Enterprises Technical

Moving Average SMA

5 Day56.27
10 Day57.75
20 Day55.94

50 Day58.24
100 Day60.75
300 Day55.49

Ambalal Sarabhai Enterprises Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

Jagsonpal Pharmaceuticals
591.65
13.55
2.34
634.95
270.05
1564.19

Ind-Swift Laboratories
106
1.95
1.87
186
89.5
626.32

Ambalal Sarabhai Enterprises
55.48
-0.37
-0.66
77.7
37.54
425.16

Brooks Laboratories
138.95
-2.8
-1.98
185.15
72.51
364.7

Pharmaids Pharmaceuticals
72.85
-3.83
-4.99
87.46
31.9
256.93

Ambalal Sarabhai Enterprises Shareholding

Shareholding Pattern

Shareholding Trend

Shareholding(%) v/s Date

View All

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

12-Nov-24
Quarterly Results

09-Aug-24
Quarterly Results

24-May-24
Audited Results

13-Feb-24
Quarterly Results

07-Nov-23
Quarterly Results

19-Aug-23
A.G.M.

10-Aug-23
Quarterly Results

30-May-23
Audited Results

10-Feb-23
Quarterly Results

09-Nov-22
Quarterly Results

Meeting Date
Announced on
Purpose

29-Jun-24
06-Jun-24
AGM

29-Mar-24
21-Feb-24
POM

08-Dec-23
02-Nov-23
POM

28-Sept-23
25-Aug-23
AGM

23-Sept-21
11-Aug-21
AGM

View All

Company Profile

ABOUT Ambalal Sarabhai Enterprises

Industry Major Drugs
ISIN INE432A01017
BSE Code 500009

Ambalal Sarabhai Enterprises Limited is an India-based company that is engaged in the business of manufacturing pharmaceuticals and electronics. The Company's segments include Pharmaceuticals and Electronics. Asence Inc., a wholly owned subsidiary of the Company, specializes in the supply of pharmaceutical preparation (finished dosage forms and active pharmaceutical ingredients) to the international markets. Its subsidiary, Sarabhai Chemicals (India) Private Limited, offers products in oncology, infertility and Uro-gynaec areas. Its wholly owned subsidiary, Suvik Hitek Private Limited, is engaged in manufacturing pharmaceutical products and marketing generics and veterinary products in the domestic market. Its subsidiary, Systronics (India) Limited, is a manufacturer of analytical and test and measuring instruments distributing its products across India. Its other subsidiaries include Synbiotics Limited, Asence Pharma Private Limited, and Sarabhai M Chemicals Limited, among others.

MANAGEMENT

Kartikeya Sarabhai Executive Chairman of the Board
Jinal Shah Chief Financial Officer
Disha Punjani Compliance Officer, Company Secretary
Chaula Shastri Whole-Time Director

AMBALAL SARABHAI ENTERPRISES SUMMARY

Ambalal Sarabhai Enterprises is trading 0.66% lower at Rs 55.48 as compared to its last closing price. Ambalal Sarabhai Enterprises has been trading in the price range of 56.65 & 53. Ambalal Sarabhai Enterprises has given 46.9% in this year & -6.53% in the last 5 days.

Ambalal Sarabhai Enterprises has TTM P/E ratio 33.75 as compared to the sector P/E of 31.15.

The company posted a net profit of 2.62 Crores in its last quarter.

Listed peers of Ambalal Sarabhai Enterprises include Jagsonpal Pharmaceuticals (2.34%), Ind-Swift Laboratories (1.87%), Ambalal Sarabhai Enterprises (-0.66%) etc.

Ambalal Sarabhai Enterprises has a 31.35% promoter holding & 68.65% public holding.

FAQs about Ambalal Sarabhai Enterprises

Ambalal Sarabhai Enterprises is trading at 55.48 as on 21 Nov, 2024 3:29:39 PM. This is -0.66% lower as compared to its previous closing price of 55.85

The market capitalization of Ambalal Sarabhai Enterprises is 428 Cr as on 21 Nov, 2024 3:29:39 PM.

The 52 wk high for Ambalal Sarabhai Enterprises is 77.7 whereas the 52 wk low is 37.54

Ambalal Sarabhai Enterprises can be analyzed on the following key metrics -

TTM P/E: 33.75
Sector P/E: 31.15
Dividend Yield: 0%
D/E ratio: -

Ambalal Sarabhai Enterprises reported a net profit of 5.68 Cr in 2024.

Ambalal Sarabhai Enterprises Quick Links

Equity Quick Links

Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks

Ambalal Sarabhai Enterprises Share Price

Price Range

Key Metrics

Ambalal Sarabhai Enterprises Analysis

Ambalal Sarabhai Enterprises Financials

Forecast

Forecast

Forecast

Ambalal Sarabhai Enterprises Technical

Ambalal Sarabhai Enterprises Peers

Ambalal Sarabhai Enterprises Shareholding

Shareholding Pattern

Shareholding Trend

Corporate Actions

Company Profile

ABOUT Ambalal Sarabhai Enterprises

MANAGEMENT

AMBALAL SARABHAI ENTERPRISES SUMMARY

FAQs about Ambalal Sarabhai Enterprises

Wait for it…

Wait for it…

Congratulations!

Subscribe to continue